# Khurram Jamil

Type: Person

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/khurram-jamil
Canonical HTML page: https://gethealthbrief.com/entity/khurram-jamil

## Timeline

- **2026-08-14**: Both companies report quarterly earnings misses — Oncobiologics EPS -$0.09 vs -$0.08 expected; Galectin EPS -$0.14 vs -$0.09 expected. OTLK closes at $0.76, GALT at $3.44.
- **2026-07-29**: Oncobiologics director Faisal Ghiath Sukhtian buys 95,398 shares — Purchase at $1.05 per share for $100,167.90; direct ownership rises to 220,972 shares.
- **2026-06-29**: Galectin insiders sell shares at $5.04 — Director Harold H. Shlevin sold 22,268 shares ($112,230.72); insider Khurram Jamil sold 47,467 shares ($239,233.68).
- **2026-05-28**: Oncobiologics director Ghiath M. Sukhtian buys 8,539,709 shares — Purchase at $0.59 per share for a total of $5.04M; direct ownership rises to 22,092,068 shares.

## Recent coverage (1 stories)

### Oncobiologics Misses EPS by $0.01, Insiders Buy $5.16M
2026-08-16 18:20:47 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

For healthcare investors, two biotech earnings misses highlight insider conviction at Oncobiologics, where directors bought $5.16M in stock, even as shares fell to $0.76. Galectin insiders sold $438K, offering a sharp behavioral contrast.
Full story: https://gethealthbrief.com/story/oncobiologics-miss-insider-buy-health

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.